SPOTLIGHT -
Benjamin Cooper, MD, Remarks on Future Analyses of TAK-676 Plus Pembrolizumab in Solid Tumors Undergoing Radiation
Benjamin Cooper, MD, discussed potential future studies exploring TAK-676 plus pembrolizumab after radiation for those with solid tumors.
Benjamin Cooper, MD, Examines Rationale Behind Combining TAK-676 With Pembrolizumab After Radiation in Select Solid Tumors
Benjamin Cooper, MD, discussed an ongoing trial examining TAK-676 in combination with pembrolizumab after radiation therapy for patients with non–small cell lung cancer, head and neck cancer, and triple-negative breast cancer.
